CIK 0001404644 · Non-accelerated filer<br>Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 980542593
- Phone
- (877) 237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-20 | Woods Keith Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2026-02-20 | Cobb Stuart Chief Scientific Officer | Grant or award | +16,500 | 37,294 | ||
| 2026-02-20 | Jordan Julie Chief Medical Officer | Grant or award | +4,900 | 13,300 | ||
| 2026-02-20 | Jordan Julie Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +29,600 | 29,600 | ||
| 2026-02-20 | Freedland Cory S. Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2026-02-20 | Noonberg Sarah B. Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2026-02-20 | PALEKAR ROHAN Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2026-02-20 | McMinn Rachel Chief Executive Officer | Grant or award | +25,900 | 1,347,659 | ||
| 2026-02-20 | McMinn Rachel Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +155,100 | 155,100 | ||
| 2026-02-20 | Cvijic Christine Mikail President and CFO | Grant or award | +22,000 | 114,643 | ||
| 2026-02-20 | Cvijic Christine Mikail President and CFO | Grant or award · Stock Option (Right to Buy) | +131,900 | 131,900 | ||
| 2026-02-20 | BAFFI ROBERT Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2025-06-12 | Woods Keith Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2025-06-12 | BAFFI ROBERT Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2025-06-12 | Woods Robert Keith Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2025-06-12 | PALEKAR ROHAN Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2025-06-12 | Freedland Cory S. Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2025-06-12 | Noonberg Sarah B. Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,050 | 12,050 | ||
| 2025-05-14 | Cobb Stuart Chief Scientific Officer | Sale 10b5-1 | −6,797 | $15.15 | $103K | 20,794 |
| 2025-03-26 | Cobb Stuart Chief Scientific Officer | Grant or award | +7,200 | 27,591 |
Page 2 of 8 · 158 trades